KR20170056521A - 항-vasa 항체, 및 이것의 제조 및 사용 방법 - Google Patents

항-vasa 항체, 및 이것의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20170056521A
KR20170056521A KR1020177005227A KR20177005227A KR20170056521A KR 20170056521 A KR20170056521 A KR 20170056521A KR 1020177005227 A KR1020177005227 A KR 1020177005227A KR 20177005227 A KR20177005227 A KR 20177005227A KR 20170056521 A KR20170056521 A KR 20170056521A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177005227A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 티 위버
보 장
Original Assignee
오바사이언스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오바사이언스, 인크. filed Critical 오바사이언스, 인크.
Publication of KR20170056521A publication Critical patent/KR20170056521A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020177005227A 2014-09-16 2015-09-16 항-vasa 항체, 및 이것의 제조 및 사용 방법 Withdrawn KR20170056521A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051130P 2014-09-16 2014-09-16
US62/051,130 2014-09-16
US201462089054P 2014-12-08 2014-12-08
US62/089,054 2014-12-08
PCT/US2015/050449 WO2016044436A2 (en) 2014-09-16 2015-09-16 Anti-vasa antibodies, and methods of production and use thereof

Publications (1)

Publication Number Publication Date
KR20170056521A true KR20170056521A (ko) 2017-05-23

Family

ID=55454121

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005227A Withdrawn KR20170056521A (ko) 2014-09-16 2015-09-16 항-vasa 항체, 및 이것의 제조 및 사용 방법

Country Status (26)

Country Link
US (4) US9403913B2 (https=)
EP (1) EP3194448A4 (https=)
JP (2) JP2017532953A (https=)
KR (1) KR20170056521A (https=)
CN (1) CN106573985A (https=)
AP (1) AP2017009758A0 (https=)
AU (1) AU2015317813B2 (https=)
BR (1) BR112017003263A2 (https=)
CA (1) CA2959179A1 (https=)
CL (1) CL2017000402A1 (https=)
CO (1) CO2017001724A2 (https=)
CR (1) CR20170067A (https=)
DO (1) DOP2017000050A (https=)
EA (1) EA201790236A1 (https=)
EC (1) ECSP17011262A (https=)
GT (1) GT201700036A (https=)
IL (1) IL250451A0 (https=)
MX (1) MX358243B (https=)
NI (1) NI201700022A (https=)
PE (1) PE20170667A1 (https=)
PH (1) PH12017500309A1 (https=)
SG (1) SG11201701016WA (https=)
SV (1) SV2017005393A (https=)
TN (1) TN2017000066A1 (https=)
TW (1) TW201619194A (https=)
WO (1) WO2016044436A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494108C2 (ru) 2006-04-07 2013-09-27 Аерпио Терапетикс, Инк. Антитела, которые связывают человеческий белок бета-тирозин фосфатазу (нртрвета), и их использование
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
BR112017003263A2 (pt) * 2014-09-16 2017-11-28 Ovascience Inc anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
BR112019001206A2 (pt) 2016-07-20 2019-06-25 Aerpio Therapeutics Inc anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
WO2020102565A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Systems and methods for nondestructive testing of gametes
KR102880907B1 (ko) 2019-11-11 2025-11-04 벤더르빌트 유니버시티 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
CN120405134A (zh) * 2024-01-30 2025-08-01 抟相医药(杭州)有限公司 基于凝聚体荧光漂白恢复技术(Drop-FRAP)的生物大分子相互作用调节剂筛选平台

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6094696A (en) * 1995-06-05 1996-12-24 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6875854B1 (en) * 1999-11-18 2005-04-05 The Brigham And Women's Hospital, Inc. Compositions and methods for the improved diagnosis and treatment of germ cell tumors
EP1233978A4 (en) 1999-11-18 2003-07-23 Brigham & Womens Hospital COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS
EP1765983A4 (en) 2004-05-17 2008-10-22 Gen Hospital Corp METHOD AND COMPOSITIONS FOR THE PRODUCTION OF STEM CELLS FROM BUTCHMARK DERIVED GLAND STEM CELLS
US7955846B2 (en) 2004-05-17 2011-06-07 The General Hospital Corporation Compositions comprising female germline stem cells and methods of use thereof
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
JPWO2006067847A1 (ja) * 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
KR20110055687A (ko) * 2008-09-25 2011-05-25 고쿠리츠 다이가쿠 호우징 도쿄 가이요우 다이가쿠 항참치 Ｖａｓａ 항체
RU2011131071A (ru) * 2008-12-26 2013-02-10 Дзе Юниверсити Оф Токио Диагностика и лечение рака с помощью антитела против lgr7
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CN106350479A (zh) 2011-04-14 2017-01-25 通用医疗公司 用于自体种系线粒体能量转移的组合物和方法
EA201490050A1 (ru) * 2011-06-29 2014-07-30 Зе Дженерэл Хоспитэл Корпорейшн Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток
JP2016503817A (ja) * 2012-12-31 2016-02-08 ディヴェロップメント センター フォー バイオテクノロジー アンチグラニュリシン抗体及びその使用方法
BR112017003263A2 (pt) * 2014-09-16 2017-11-28 Ovascience Inc anticorpos anti-vasa, e métodos de produção e utilização dos mesmos
WO2016115077A1 (en) * 2015-01-13 2016-07-21 President And Fellows Of Harvard College Purification of germ stem cells by targeting mrp9

Also Published As

Publication number Publication date
TW201619194A (zh) 2016-06-01
PE20170667A1 (es) 2017-06-06
US20160311929A1 (en) 2016-10-27
GT201700036A (es) 2018-12-19
AU2015317813B2 (en) 2018-04-05
US20170107299A1 (en) 2017-04-20
CR20170067A (es) 2017-05-10
US20180155445A1 (en) 2018-06-07
BR112017003263A2 (pt) 2017-11-28
SG11201701016WA (en) 2017-03-30
JP2017532953A (ja) 2017-11-09
WO2016044436A3 (en) 2016-06-09
AP2017009758A0 (en) 2017-02-28
AU2015317813A1 (en) 2017-03-02
CN106573985A (zh) 2017-04-19
CO2017001724A2 (es) 2017-07-19
ECSP17011262A (es) 2017-05-31
US9403913B2 (en) 2016-08-02
PH12017500309A1 (en) 2017-07-10
CL2017000402A1 (es) 2017-11-03
NI201700022A (es) 2017-05-04
JP2018148915A (ja) 2018-09-27
SV2017005393A (es) 2017-06-07
IL250451A0 (en) 2017-03-30
MX2017002390A (es) 2017-07-28
US9567404B2 (en) 2017-02-14
TN2017000066A1 (en) 2018-07-04
DOP2017000050A (es) 2018-04-15
EP3194448A4 (en) 2018-03-14
WO2016044436A2 (en) 2016-03-24
EP3194448A2 (en) 2017-07-26
US20160075797A1 (en) 2016-03-17
EA201790236A1 (ru) 2017-11-30
CA2959179A1 (en) 2016-03-24
MX358243B (es) 2018-08-10

Similar Documents

Publication Publication Date Title
CN117098561A (zh) Ccr8抗体及其应用
CN112424223B (zh) 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
KR20170056521A (ko) 항-vasa 항체, 및 이것의 제조 및 사용 방법
US20140242095A1 (en) Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP7766870B2 (ja) 拮抗的抗原結合タンパク質
JP6660957B2 (ja) 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
AU2017260232B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
AU2022252731B2 (en) Protein Binders For iRhom2
CN112334484A (zh) 抗-CD3ε抗体及其应用方法
CN116925233A (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
CN118946588A (zh) 抗pvrig抗体、其药物组合物及用途
JP7837331B2 (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
KR20230169950A (ko) Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체
JP2025524347A (ja) ガンマデルタｔ細胞受容体に結合するバリアント抗体
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
JP2022550121A (ja) Ｌｉｆに特異的な結合分子及びその使用
KR20260051068A (ko) Enpp3 및 cd3 결합제 및 이의 사용 방법
CN117247453A (zh) 抗CD19 scFv FMC63序列的单克隆抗体及其制备和应用
EP4438624A1 (en) Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2024094151A1 (en) Multi-specific antibody and medical use thereof
HK1236552A1 (en) Anti-vasa antibodies, and methods of production and use thereof
TW202412838A (zh) 包含結合γ-δ T細胞受體之抗體之組合物
OA18333A (en) Anti-Vasa antibodies, and methods of production and use thereof
RU2812875C1 (ru) Индуцирующий цитотоксичность терапевтический агент

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination